138 related articles for article (PubMed ID: 37596839)
21. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract][Full Text] [Related]
23. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
24. Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ahmed R; Ornstein MC
Curr Treat Options Oncol; 2023 Sep; 24(9):1183-1198. PubMed ID: 37403008
[TBL] [Abstract][Full Text] [Related]
25. Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series.
Ercanbrack CW; Elhusseiny AM; Sanders RN; Santos Horta E; Uwaydat SH
Am J Ophthalmol Case Rep; 2024 Mar; 33():102011. PubMed ID: 38374949
[TBL] [Abstract][Full Text] [Related]
26. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
27. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
28. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
31. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
32. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
[TBL] [Abstract][Full Text] [Related]
33. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic analysis of axitinib in healthy volunteers.
Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.
Zhou X; Ouerdani A; Diderichsen PM; Gupta N
J Clin Pharmacol; 2022 Mar; 62(3):422-433. PubMed ID: 34564871
[TBL] [Abstract][Full Text] [Related]
36. Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.
Takamori H; Yamasaki T; Kitadai R; Minamishima YA; Nakamura E
Cancer Sci; 2023 Apr; 114(4):1208-1217. PubMed ID: 36650918
[TBL] [Abstract][Full Text] [Related]
37. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
39. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Hurkmans DP; Basak EA; van Dijk T; Mercieca D; Schreurs MWJ; Wijkhuijs AJM; Bins S; Hoop EO; Debets R; Joerger M; Odink A; van der Veldt AAM; van der Leest CH; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2019 Jul; 7(1):192. PubMed ID: 31324223
[TBL] [Abstract][Full Text] [Related]
40. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
